End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.55 CNY | -2.47% |
|
-4.89% | -33.43% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- With a P/E ratio at 10.61 for the current year and 9.14 for next year, earnings multiples are highly attractive compared with competitors.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.43% | 3.75B | B- | ||
+52.09% | 816B | C+ | ||
+38.59% | 634B | B | ||
-7.45% | 351B | C+ | ||
+15.25% | 323B | B- | ||
+5.64% | 293B | C+ | ||
+13.40% | 238B | B+ | ||
+0.61% | 222B | A+ | ||
+13.24% | 218B | B- | ||
+6.67% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600079 Stock
- Ratings Humanwell Healthcare (Group) Co.,Ltd.